Having trouble accessing articles? Reset your cache.

Zymafos palifosfamide: Development discontinued

Ziopharm discontinued development of Zymafos as first-line treatment of STS after the double-blind, international Phase III PICASSO 3 trial in 447 anthracycline-naïve patients with metastatic STS showed that IV Zymafos plus doxorubicin missed the primary

Read the full 353 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE